Alamar Launches National Biomarker Initiative for Alzheimer's with Top Universities
ALMR sits 51% above its 52-week low of $18.845.
Summary
Alamar Biosciences is partnering with leading research universities to launch a national-scale proteomics initiative using its NULISAseq Neuro 220 panel. The project will profile approximately 21,000 plasma samples from 10,000 Alzheimer's Disease and Related Dementias participants, generating a large, publicly accessible dataset linked to NACC IDs. This collaboration, part of the CLARiTI portfolio, leverages academic and philanthropic partnerships and includes an AI-driven data challenge. The initiative validates Alamar's platform at scale and positions it as a key player in neurodegenerative biomarker discovery, potentially accelerating adoption and future revenue. The stock is trading near its 52-week high, reflecting strong post-IPO momentum.
At the time of this announcement, ALMR was trading at $28.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $18.85 to $28.68. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.